“[18F]FDG PET Immunotherapy Radiomics Signature (iRADIOMICS) Predicts Response of Non-Small-Cell Lung Cancer Patients Treated With Pembrolizumab”. Radiology and Oncology, vol. 54, no. 3, Sept. 2020, pp. 285-94, https://www.radioloncol.com/index.php/ro/article/view/3452.